Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$399799.0.

  • China Pharma Holdings' Net Cash Flow fell 119430.87% to -$399799.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$417862.0, marking a year-over-year increase of 3777.53%. This contributed to the annual value of -$764365.0 for FY2024, which is 1979.55% down from last year.
  • China Pharma Holdings' Net Cash Flow amounted to -$399799.0 in Q3 2025, which was down 119430.87% from $254149.0 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Net Cash Flow high stood at $4.4 million for Q4 2021, and its period low was -$1.4 million during Q2 2022.
  • In the last 5 years, China Pharma Holdings' Net Cash Flow had a median value of -$65874.0 in 2024 and averaged -$20401.8.
  • As far as peak fluctuations go, China Pharma Holdings' Net Cash Flow soared by 929863.04% in 2023, and later plummeted by 183509.07% in 2024.
  • China Pharma Holdings' Net Cash Flow (Quarter) stood at $4.4 million in 2021, then tumbled by 101.36% to -$60201.0 in 2022, then surged by 105.86% to $3528.0 in 2023, then tumbled by 1835.09% to -$61214.0 in 2024, then crashed by 553.12% to -$399799.0 in 2025.
  • Its Net Cash Flow stands at -$399799.0 for Q3 2025, versus $254149.0 for Q2 2025 and -$210998.0 for Q1 2025.